J Drugs Dermatol. 2020 Nov 1;19(11):1056-1064. doi: 10.36849/JDD.2020.5648.
Transient acantholytic dermatosis has been frequently reported in patients with malignancies. While paraneoplastic cases have rarely been reported, most eruptions occur in the setting of chemotherapeutic agents. Management is based on limited data and primarily with topical steroids and topical emollients. A subset of patients exhibits recalcitrant disease and require alternate therapeutic approachesMethods: This systematic review consisted of identifying records in PubMed using the medical subject headings (MeSH) terms “chemotherapy” AND “Grover”, “chemotherapy” AND “Grover’s”, “cancer” AND “Grover”, “cancer” AND “Grover’s”, “malignancy” AND “Grover”, “malignancy” AND “Grover’s”, as well as a free text search for “Grover” OR “Grover’s” OR “Grover disease” OR “Grovers disease” OR “Grover’s disease” OR “transient acantholytic dermatosis” OR “transient acantholytic” to identify case reports, case series, systematic reviews, review articles, meta-analyses, clinical trials, brief commentaries, and original articles. The titles and abstracts of all results were reviewed. Full texts of relevant results were then read in their entirety and applicability was determined.
Overall, Grover disease has rarely been reported in the setting of malignancy. When it occurs, it is generally in the setting of chemotherapy use. Chemotherapy-associated Grover disease is reported most frequently in association with cytotoxic chemotherapies, followed by small molecule inhibitors. The first line treatment for this complication is the use of topical agents. When these provide inadequate relief, alternate therapies have been rarely reported, with novel treatments proposed based on the type of chemotherapy agent and its mechanism of action.
Chemotherapy-associated Grover disease is an uncommon complication of cancer treatment. While most cases of chemotherapy-associated Grover disease can be treated with topical steroids and topical emollients, certain cases require a more specialized approach. This could include adjuvant adjuvant therapies, or novel treatments that are directly related to the mechanism of action of the chemotherapy involved. J Drugs Dermatol. 2020;19(11):1056-1064. doi:10.36849/JDD.2020.5648.
暂时性棘层松解性皮肤病常发生于恶性肿瘤患者。虽然报道的副肿瘤病例很少，但大多数皮疹发生于化疗药物治疗中。治疗基于有限的数据，主要是使用局部皮质类固醇和局部保湿剂。一部分患者表现为难治性疾病，需要替代治疗方法。
本系统评价通过使用医学主题词(MeSH)术语“化疗”和“Grover”、“化疗”和“Grover's”、“癌症”和“Grover”、“癌症”和“Grover's”、“恶性肿瘤”和“Grover”、“恶性肿瘤”和“Grover's”在 PubMed 中识别记录，以及对“Grover”或“Grover's”或“Grover 病”或“Grovers 病”或“Grover's 病”或“暂时性棘层松解性皮肤病”或“暂时性棘层松解”的自由文本搜索来识别病例报告、病例系列、系统评价、综述文章、荟萃分析、临床试验、简要评论和原始文章。审查了所有结果的标题和摘要。然后阅读了相关结果的全文，并确定了其适用性。
总体而言，恶性肿瘤中很少报道 Grover 病。当发生时，通常是在化疗药物使用的情况下。与化疗相关的 Grover 病最常与细胞毒性化疗药物相关，其次是小分子抑制剂。这种并发症的一线治疗是使用局部药物。当这些药物不能充分缓解时，很少有报道替代治疗方法，根据化疗药物的类型及其作用机制提出了新的治疗方法。
与化疗相关的 Grover 病是癌症治疗的一种罕见并发症。虽然大多数与化疗相关的 Grover 病可以用局部皮质类固醇和局部保湿剂治疗，但某些病例需要更专门的方法。这可能包括辅助辅助治疗，或直接与所涉及的化疗药物作用机制相关的新疗法。J 皮肤病药物。2020;19(11):1056-1064.doi:10.36849/JDD.2020.5648.
